News | February 24, 2016

Carillon Mitral Contour System Associated with Significant Functional Mitral Regurgitation Improvement

Device offers short procedure times, ease of implantation and compatibility with other cardiac therapies

Carillon mitral contour system, Cardiac Dimensions, functional mitral regurgitation, FMR, University Hospital Liepzig study

February 24, 2016 — A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in significant improvement of functional mitral regurgitation (FMR), a condition that can increase the symptoms of heart failure. The study was recently published in the Journal of Invasive Cardiology.

The Carillon device is a percutaneous mitral annuloplasty treatment option that can be deployed rapidly and safely, utilizing standard interventional techniques. Through multiple clinical trials, the device has demonstrated compelling efficacy, significantly improving patients’ symptoms, mitral regurgitation and quality of life.

Researchers of the study noted that percutaneous treatment for FMR is clinically valuable due to the widespread prevalence of the problem and the lack of alternative available therapies.

“In this ‘real-life’ setting, we observed a marked reduction in FMR and continued improvement in the condition over time, with the majority of patients experiencing clinical success similar to the results of the TITAN Trial,” said Norbert Klein, M.D. University Hospital Leipzig, Department of Cardiology and Angiology and lead author of the study. “In addition, we experienced short procedure times, ease of implantation and compatibility with other cardiac therapies.”

Data were collected from a prospective, single-center, non-randomized observational analysis of 17 consecutive patients with moderate to severe FMR, despite stable optimal medical drug treatment. Patients were selected for percutaneous rather than surgical approach due to high surgical risk as assessed by EuroSCORE II and STS score.

The implantable device consists of a distal anchor and a proximal anchor connected by a shaping ribbon and utilizes the heart’s venous anatomy to reshape the mitral annulus. This approach allows for reduction of the dilated annulus, addressing a root cause of FMR.

The device is approved for use in Europe. It is not approved for use in the United States.

For more information: www.cardiacdimensions.com

Related Content

News | Heart Valve Technology

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality ...

Home November 09, 2021
Home
Feature | Heart Valve Technology

July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve ...

Home July 08, 2021
Home
News | Heart Valve Technology

June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its heart ...

Home June 02, 2021
Home
News | Heart Valve Technology

May 4, 2021 – A new study, presented at the 2021 American Association for Thoracic Surgery (AATS) 101st annual meeting ...

Home May 04, 2021
Home
News | Heart Valve Technology

March 18, 2020 — A groundbreaking new study led by University of Minnesota Twin Cities researchers from both the College ...

Home March 18, 2021
Home
News | Heart Valve Technology

February 4, 2021 — Transcatheter aortic valve replacement (TAVR) has historically only been used with caution in the ...

Home February 04, 2021
Home
News | Heart Valve Technology

January 20, 2021 — The U.S. Centers for Medicare and Medicaid Services (CMS) revised its National Coverage Determination ...

Home January 20, 2021
Home
News | Heart Valve Technology

December 14, 2020 - Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an ...

Home December 14, 2020
Home
Feature | Heart Valve Technology

November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more ...

Home November 17, 2020
Home
Feature | Heart Valve Technology | Dave Fornell, Editor

November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge ...

Home November 17, 2020
Home
Subscribe Now